Log In
Print
BCIQ
Print
Print this Print this
 

Topical XEN402, TV-45070

  Manage Alerts
Collapse Summary General Information
Company Xenon Pharmaceuticals Inc.
DescriptionTopical formulation of sodium channel sub-type Nav1.7 (SCN9A) blocker
Molecular Target Nav1.7 (SCN9A)
Mechanism of ActionNa channel blocker
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationPain
Indication DetailsTreat osteoarthitis (OA) pain; Treat pain associated with erythromelalgia; Treat postherpetic neuralgia (PHN)
Regulatory Designation

U.S. - Orphan Drug (Treat pain associated with erythromelalgia)

Partner

Teva Pharmaceutical Industries Ltd.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$376.0M

$41.0M

$335.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today